NCT05302284View on ClinicalTrials.gov

A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma

PHASE3RecruitingINTERVENTIONAL
Enrollment

452

Participants

Timeline

Start Date

June 14, 2022

Primary Completion Date

December 31, 2026

Study Completion Date

April 30, 2028

Conditions
Urothelial CarcinomaHER2-expressing
Interventions
DRUG

RC48-ADC

2.0 mg/kg IV every 2 weeks

DRUG

Toripalimab

3.0 mg/kg IV every 2 weeks

DRUG

Gemcitabine

1000mg/m2 IV infusion on Days 1 and 8 of every 3 week cycle

DRUG

Cisplatin

70mg/m2 IV infusion on Day 1 of every 3 week cycle

DRUG

Carboplatin

AUC=4.5, IV infusion on Day 1 of every 3 week cycle

Trial Locations (2)

Unknown

RECRUITING

Cancer Hospital Chinese Academy of Medical Sciences, Beijing

RECRUITING

Beijing Cancer Hospital, Beijing

All Listed Sponsors
lead

RemeGen Co., Ltd.

INDUSTRY